Pfizer says its vaccine targeting Omicron will be ready in March


Pfizer will have a COVID-19 vaccine that particularly targets the Omicron variant ready by March, the pharmaceutical company’s chief govt stated Monday. 

Pfizer CEO Albert Bourla stated the company has already begun manufacturing a brand new model of its COVID-19 vaccine that goals to guard recipients towards Omicron. “This vaccine will be ready in March,” he instructed CNBC’s “Squawk Box” on Monday. “We [are] already starting manufacturing some of these quantities at risk.”

Last week, Omicron made up greater than 95% of all new COVID-19 circumstances in the U.S., in response to the Centers for Disease Control and Prevention. 

CDC clarifies isolation tips


Pfizer additionally stated it’s working to enhance its present vaccine formulation, developed collectively with Germany’s BioNTech, based mostly on the vaccine’s response to new COVID-19 variants that come up. Pfizer can “update the current vaccine to address any future variant of potential concern, if needed,” a company spokesperson stated in an announcement to CBS MoneyWatch. 

“In the event that a third dose with the current vaccine is not found to protect against the Omicron variant or other future variants, Pfizer expects to be able to develop and produce a tailor-made vaccine against that variant in approximately 100 days, subject to regulatory approval,” the spokesperson added. 

The spokesperson confirmed that it has already begun manufacturing doses of the Omicron-specific vaccine, ought to it be deemed mandatory.

White House chief medical adviser Dr. Anthony Fauci in December predicted that Omicron would change into the dominant virus pressure in the U.S., however he has not stated {that a} new Omicron-specific shot is important to take care of immunity. Fauci as an alternative urged Americans to get booster pictures, which research have proven present higher safety towards Omicron. 

A current study from the U.Okay. Health Security Agency discovered that booster pictures are as much as 75% efficient at stopping symptomatic COVID-19 an infection brought on by Omicron.

Booster shot is first line of protection

Moderna on Monday stated in an replace on its website that whereas the pharmaceutical agency’s first line of protection towards Omicron is a 3rd dose of its present vaccine, it’s also growing an Omicron-specific booster shot.

“Given the long-term threat demonstrated by Omicron’s immune escape, Moderna will continue to develop an Omicron-specific variant vaccine,” the company stated. Moderna expects the vaccine to enter superior scientific trials early this year, however didn’t specify when. 

Moderna CEO Stéphane Bancel stated at Goldman Sachs’ Healthcare CEO Conference final week that he expects safety supplied by the booster towards Omicron to wane. “I would expect that it’s not going to hold great,” he stated, referring to the efficacy of a 3rd vaccine dose over time. 

Bancel additionally stated the company is engaged on an Omicron-specific vaccine candidate that he expects to enter scientific trials “very soon.” On Monday, at J.P. Morgan’s fortieth Annual Healthcare Conference, Bancel reiterated that the company is “working on an Omicron-specific booster.” 

Download our Free App

For Breaking News & Analysis Download the Free CBS News app


Please enter your comment!
Please enter your name here